DDInter1059 DDInter899
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Levomilnacipran {u} (Compound) resembles {v} (Compound) Milnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP2C19
Levomilnacipran {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Levomilnacipran {u} (Compound) downregulates {v} (Gene) GJA1
Levomilnacipran {u} (Compound) causes {v} (Side Effect) Infection
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Doxepin
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Levomilnacipran (Compound) resembles Milnacipran (Compound)
Levomilnacipran (Compound) binds CYP2C19 (Gene)
Levomilnacipran (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Levomilnacipran (Compound) downregulates GJA1 (Gene)
Levomilnacipran (Compound) causes Infection (Side Effect)
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Levomilnacipran may lead to a major life threatening interaction when taken with Doxepin
Levomilnacipran may lead to a major life threatening interaction when taken with Methylene blue
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Levomilnacipran may lead to a major life threatening interaction when taken with Iobenguane